

Applicants also note that some of the co-inventors have yet another co-pending application, which is United States Serial No. 07/704,540, filed May 23, 1991.

Applicants also note that in parent application Serial No. 07/367,090, filed June 16, 1989 (now abandoned), they filed a copy of the European Search Report and the 1449 Forms and documents set forth in the 1449 Form.

Claims 1, 3 and 5 have been cancelled.

Applicants request reconsideration of Claims 10 and 11, rejected under 35 USC §103 over Aristoff, et al. (R) and Rubin, et al. (S).

In support of the patentability of Claims 10 and 11, Applicants submit herewith the declaration of Dr. Walker Long (MD).

It is noted that the claims are directed to treating "pulmonary" hypertension.

As stated by Dr. Walker Long, Aristoff, et al., "teaches that certain benzidine prostaglandins are capable of lowering blood pressure in rats. The assay which was used to determine this effect measures changes in systemic blood pressure in rats, not

pulmonary blood pressure" (see paragraph 9 of the Walker Long Declaration).


In view of the declaration of Dr. Walker Long (in particular, paragraph 5 (on pages 2 through 7)), it is clear that neither of the cited references teaches alone or if combined, the invention of Claims 10 and 11.

Respectfully submitted,

DIKE, BRONSTEIN, ROBERTS & CUSHMAN

Date: January 30, 1992

By


Donald Brown (Reg. No. 20845)
Attorney for Applicant(s)
130 Water Street
Boston, MA 02109
617/523-3400